Canada markets close in 1 hour 27 minutes
  • S&P/TSX

    20,200.12
    -0.53 (-0.00%)
     
  • S&P 500

    4,248.93
    +2.49 (+0.06%)
     
  • DOW

    33,920.64
    -24.94 (-0.07%)
     
  • CAD/USD

    0.8129
    +0.0003 (+0.03%)
     
  • CRUDE OIL

    73.00
    +0.15 (+0.21%)
     
  • BTC-CAD

    41,086.37
    +513.54 (+1.27%)
     
  • CMC Crypto 200

    801.62
    -8.58 (-1.06%)
     
  • GOLD FUTURES

    1,781.60
    +4.20 (+0.24%)
     
  • RUSSELL 2000

    2,312.20
    +16.26 (+0.71%)
     
  • 10-Yr Bond

    1.4900
    +0.0180 (+1.22%)
     
  • NASDAQ

    14,282.01
    +28.75 (+0.20%)
     
  • VOLATILITY

    16.26
    -0.40 (-2.40%)
     
  • FTSE

    7,074.06
    -15.95 (-0.22%)
     
  • NIKKEI 225

    28,874.89
    -9.24 (-0.03%)
     
  • CAD/EUR

    0.6810
    +0.0006 (+0.09%)
     

C4 Therapeutics to Present at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

WATERTOWN, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming investor conferences:

  • UBS Global Healthcare Conference on Wednesday, May 26, 2021 at 8:00 a.m. ET

  • Jefferies Healthcare Conference on Tuesday, June 1, 2021 at 10:30 a.m. ET

A live webcast of each event can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. Replays of the webcasts will be archived on the C4T website for at least two weeks following the applicable presentation date.

About C4 Therapeutics
C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.

CONTACT: Investor & Media Contact Kendra Adams SVP, Communications & Investor Relations Kendra.Adams@c4therapeutics.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting